| Rank |
Title |
Journal |
Year |
PubWeight™‹?› |
|
1
|
Survival, durable tumor remission, and long-term safety in patients with advanced melanoma receiving nivolumab.
|
J Clin Oncol
|
2014
|
9.86
|
|
2
|
Antagonist antibodies to PD-1 and B7-H1 (PD-L1) in the treatment of advanced human cancer.
|
Clin Cancer Res
|
2013
|
3.48
|
|
3
|
Breathing new life into immunotherapy: review of melanoma, lung and kidney cancer.
|
Nat Rev Clin Oncol
|
2013
|
2.64
|
|
4
|
The Next Immune-Checkpoint Inhibitors: PD-1/PD-L1 Blockade in Melanoma.
|
Clin Ther
|
2015
|
1.73
|
|
5
|
Emerging targeted agents in metastatic breast cancer.
|
Nat Rev Clin Oncol
|
2013
|
1.59
|
|
6
|
Combination cancer immunotherapies tailored to the tumour microenvironment.
|
Nat Rev Clin Oncol
|
2015
|
1.54
|
|
7
|
Trial watch: Monoclonal antibodies in cancer therapy.
|
Oncoimmunology
|
2013
|
1.41
|
|
8
|
Intratumoral immunization: a new paradigm for cancer therapy.
|
Clin Cancer Res
|
2014
|
1.24
|
|
9
|
Nivolumab in NSCLC: latest evidence and clinical potential.
|
Ther Adv Med Oncol
|
2015
|
1.21
|
|
10
|
Development of PD-1/PD-L1 Pathway in Tumor Immune Microenvironment and Treatment for Non-Small Cell Lung Cancer.
|
Sci Rep
|
2015
|
1.18
|
|
11
|
Pathways and therapeutic targets in melanoma.
|
Oncotarget
|
2014
|
1.17
|
|
12
|
Molecular pathways and therapeutic targets in lung cancer.
|
Oncotarget
|
2014
|
1.16
|
|
13
|
Immune modulation for cancer therapy.
|
Br J Cancer
|
2014
|
1.15
|
|
14
|
Nivolumab in melanoma: latest evidence and clinical potential.
|
Ther Adv Med Oncol
|
2015
|
1.09
|
|
15
|
Cancer immunotherapy in clinical practice -- the past, present, and future.
|
Chin J Cancer
|
2014
|
0.98
|
|
16
|
Trial Watch: Immunostimulatory cytokines.
|
Oncoimmunology
|
2013
|
0.96
|
|
17
|
Checkpoint modulation in melanoma: an update on ipilimumab and future directions.
|
Curr Oncol Rep
|
2013
|
0.94
|
|
18
|
New modalities of cancer treatment for NSCLC: focus on immunotherapy.
|
Cancer Manag Res
|
2014
|
0.94
|
|
19
|
Immune checkpoint blockade in cancer treatment: a double-edged sword cross-targeting the host as an "innocent bystander".
|
Toxins (Basel)
|
2014
|
0.92
|
|
20
|
The future of glioblastoma therapy: synergism of standard of care and immunotherapy.
|
Cancers (Basel)
|
2014
|
0.91
|
|
21
|
Immunotherapy for prostate cancer: recent developments and future challenges.
|
Cancer Metastasis Rev
|
2014
|
0.90
|
|
22
|
Anticancer Cytokines: Biology and Clinical Effects of Interferon-α2, Interleukin (IL)-2, IL-15, IL-21, and IL-12.
|
Semin Oncol
|
2015
|
0.89
|
|
23
|
Recombinant interleukin-21 plus sorafenib for metastatic renal cell carcinoma: a phase 1/2 study.
|
J Immunother Cancer
|
2014
|
0.83
|
|
24
|
IL-21: a pleiotropic cytokine with potential applications in oncology.
|
J Immunol Res
|
2015
|
0.83
|
|
25
|
Immunotherapy for solid tumors--a review for surgeons.
|
J Surg Res
|
2013
|
0.83
|
|
26
|
Tertiary Lymphoid Structures in Cancers: Prognostic Value, Regulation, and Manipulation for Therapeutic Intervention.
|
Front Immunol
|
2016
|
0.83
|
|
27
|
Targeting CD8+ T-cell tolerance for cancer immunotherapy.
|
Immunotherapy
|
2014
|
0.81
|
|
28
|
Clinical utility of nivolumab in the treatment of advanced melanoma.
|
Ther Clin Risk Manag
|
2016
|
0.81
|
|
29
|
PD-1 and PD-L1 antibodies for melanoma.
|
Hum Vaccin Immunother
|
2014
|
0.80
|
|
30
|
Elevated Expression of CD160 and 2B4 Defines a Cytolytic HIV-Specific CD8+ T-Cell Population in Elite Controllers.
|
J Infect Dis
|
2015
|
0.80
|
|
31
|
Immune Checkpoint Modulation in Colorectal Cancer: What's New and What to Expect.
|
J Immunol Res
|
2015
|
0.78
|
|
32
|
Trial watch: Tumor-targeting monoclonal antibodies for oncological indications.
|
Oncoimmunology
|
2015
|
0.77
|
|
33
|
Trial Watch-Immunostimulation with cytokines in cancer therapy.
|
Oncoimmunology
|
2015
|
0.77
|
|
34
|
Adding fuel to the fire: immunogenic intensification.
|
Hum Vaccin Immunother
|
2014
|
0.75
|